K Number
K122821
Device Name
CELLTRACKS AUTOPREP SYSTEM
Manufacturer
Date Cleared
2012-12-13

(90 days)

Product Code
Regulation Number
866.6020
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The CELLTRACKS® AUTOPREP® System is a laboratory instrument used with immunomagnetic reagents that capture and enrich target cells, and labeling reagents that differentiate cells in whole blood. The CELLTRACKS ANALYZER II® may be used for cell identification and enumeration. The system is for in vitro diagnostic use.
Device Description
The CELLTRACKS® AUTOPREP® System is a general purpose laboratory instrument used with immunomagnetic reagents that capture and enrich target cells, and labeling reagents that differentiate cells in whole blood. The CELLTRACKS® AUTOPREP® System processes up to 8 samples in a batch, performing all required process steps, including red cell detection, plasma aspiration and final transfer to the analysis cartridge. The user is prompted to perform various pre-processing operations such as dilution and centrifugation. Cell analyzers such as the CELLTRACKS ANALYZER II® may be used for cell identification and enumeration following processing. The CELLTRACKS® AUTOPREP® system uses a series of immunomagnetic separation procedures to isolate the cells of interest and to stain the cells with fluorescence-labeled monoclonal antibodies.
More Information

Not Found

No
The description focuses on immunomagnetic separation and automated processing steps, with no mention of AI or ML for cell identification or enumeration. The analysis is performed by a separate analyzer.

No
The device is described as a "laboratory instrument" for "in vitro diagnostic use" to capture, enrich, identify, and enumerate cells, which are diagnostic functions, not therapeutic.

Yes

The "Intended Use / Indications for Use" section explicitly states, "The system is for in vitro diagnostic use." The "Device Description" also describes its function in preparing samples for cell identification and enumeration, which are diagnostic purposes.

No

The device description clearly states it is a "laboratory instrument" and describes physical processes like "plasma aspiration" and "final transfer to the analysis cartridge," indicating it is a hardware device with associated software, not a software-only device.

Yes, the provided text explicitly states that the CELLTRACKS® AUTOPREP® System is an IVD (In Vitro Diagnostic).

The "Intended Use / Indications for Use" section clearly states: "The system is for in vitro diagnostic use."

N/A

Intended Use / Indications for Use

The CELLTRACKS® AUTOPREP® System is a laboratory instrument used with immunomagnetic reagents that capture and enrich target cells, and labeling reagents that differentiate cells in whole blood. The CELLTRACKS ANALYZER II® may be used for cell identification and enumeration. The system is for in vitro diagnostic use.

Product codes

NQI

Device Description

The CELLTRACKS® AUTOPREP® System is a general purpose laboratory instrument used with immunomagnetic reagents that capture and enrich target cells, and labeling reagents that differentiate cells in whole blood. The CELLTRACKS® AUTOPREP® System processes up to 8 samples in a batch, performing all required process steps, including red cell detection, plasma aspiration and final transfer to the analysis cartridge. The user is prompted to perform various pre-processing operations such as dilution and centrifugation. Cell analyzers such as the CELLTRACKS ANALYZER II® may be used for cell identification and enumeration following processing. The CELLTRACKS® AUTOPREP® system uses a series of immunomagnetic separation procedures to isolate the cells of interest and to stain the cells with fluorescence-labeled monoclonal antibodies.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Non-clinical testing for the CELLTRACKS® AUTOPREP® System functional testing included:
• New reagent probe versus current reagent probe assay performance equivalence
• CTC (circulating tumor cell) spike level characterization of the new probe (tumor cell carryover and control cell carryover)
• Run to Run carryover characterization
• Reliability/Life testing
The information presented in the premarket notification demonstrates that the performance of the CELLTRACKS® AUTOPREP® System (modified) is substantially equivalent to the predicate device.
Equivalence was demonstrated through non-clinical functional testing for the modified device. The information presented in the premarket notification provides a reasonable assurance that the CELLTRACKS® AUTOPREP® System (modified) is as safe and effective as the predicate device for the stated intended use.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K110406

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 866.6020 Immunomagnetic circulating cancer cell selection and enumeration system.

(a)
Identification. An immunomagnetic circulating cancer cell selection and enumeration system is a device that consists of biological probes, fluorochromes, and other reagents; preservation and preparation devices; and a semiautomated analytical instrument to select and count circulating cancer cells in a prepared sample of whole blood. This device is intended for adjunctive use in monitoring or predicting cancer disease progression, response to therapy, and for the detection of recurrent disease.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System.” See § 866.1(e) for availability of this guidance document.

0

Ki22821

8.0 510(K) SUMMARY

DEC 1 3 2012

1 -

Submitter's NameVeridex, LLC
Address1001 US Highway 202
Raritan, NJ 08869-0606
Telephone Number
Fax Number908-927-4947
908-526-5059
Contact PersonKimberly Prescott, Associate Director, Global Regulatory Affairs
Date:December 6, 2012
Name of the DeviceCELLTRACKS® AUTOPREP® System
Common or Usual
NameAutomated Blood Cell Diluting Apparatus
Name: Immunomagnetic circulating cancer cell selection and enumeration
system
Classification NameDevice Class: II
Product Code: NQI
Regulation Number: 21 CFR 866.6020
Performance StandardsThere are no performance standards promulgated for this device.
Indications for UseThe CELLTRACKS® AUTOPREP® System is a laboratory instrument
used with immunomagnetic reagents that capture and enrich target cells,
and labeling reagents that differentiate cells in whole blood.
The CELLTRACKS ANALYZER II® may be used for cell identification
and enumeration. The system is for in vitro diagnostic use.
CELLTRACKS® AUTOPREP® System
Identification of the
Legally Marketed
Device
(Predicate Device)Name: Immunomagnetic circulating cancer cell selection and enumeration
system
Device Class: II
Product Code: NQI
Regulation Number: 21 CFR 866.6020

1

510(k) Summary, continued

ﻧﻪ

| Device Description | The CELLTRACKS® AUTOPREP® System is a general purpose
laboratory instrument used with immunomagnetic reagents that capture
and enrich target cells, and labeling reagents that differentiate cells in
whole blood. The CELLTRACKS® AUTOPREP® System processes
up to 8 samples in a batch, performing all required process steps,
including red cell detection, plasma aspiration and final transfer to the
analysis cartridge. The user is prompted to perform various pre-
processing operations such as dilution and centrifugation. Cell
analyzers such as the CELLTRACKS ANALYZER II® may be used
for cell identification and enumeration following processing.
The CELLTRACKS® AUTOPREP® system uses a series of
immunomagnetic separation procedures to isolate the cells of interest
and to stain the cells with fluorescence-labeled monoclonal antibodies. |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Comparison to
Predicate Device | The CELLTRACKS® AUTOPREP® System (modified) is
substantially equivalent to the CELLTRACKS® AUTOPREP®
System (current - K110406, January 20, 2012). There has been no
change to intended use, fundamental scientific technology, mode of
operations, or specimen type/identification.
The only change from the predicate device and subject of this Special
510(k) is a modification to the pipetting probe to reduce the potential
for carryover, and a label change to the CELLTRACKS®
AUTOPREP® System labeling to change the caution about carryover
from circulating tumor cell (CTC) samples when containing 5,000
CTCs or greater per 7.5mL of blood. |
| Description of Testing | Non-clinical testing for the CELLTRACKS® AUTOPREP® System
functional testing included:
• New reagent probe versus current reagent probe assay
performance equivalence
• CTC (circulating tumor cell) spike level characterization of the
new probe (tumor cell carryover and control cell carryover)
• Run to Run carryover characterization
• Reliability/Life testing |

.

. .

.

:

:

·

2

Image /page/2/Figure/0 description: The image shows the words "Conclusion of Testing" in a large, bold font. The text is located on the left side of the image. The background of the image is white with some light gray spots.

The information presented in the premarket notification demonstrates that the performance of the CELLTRACKS® AUTOPREP® System (modified) is substantially equivalent to the predicate device.

Equivalence was demonstrated through non-clinical functional testing for the modified device. The information presented in the premarket notification provides a reasonable assurance that the CELLTRACKS® AUTOPREP® System (modified) is as safe and effective as the predicate device for the stated intended use.

3

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002

Letter Date: December 13, 2012

Veridex, LLC C/O Ms. Kimberly Prescott. 1001 US Highway 202 Raritan, NJ 08869-1424

Re: 510(k) Number:K122821
Trade/Device Name:CELLTRACKS AUTOPREP® System
Regulation Number:21 CFR 866.6020
Regulation Name:Immunomagnetic circulating cancer cell selection and enumeration
system
Regulatory Class:Class II
Product Code:NQI
Dated:November 8, 2012
Received:November 9, 2012

Dear Ms. Prescott:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

4

Page 2 - Ms. Kimberly Prescott

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Reena Philip -S

for

Maria M. Chan, Ph.D.

Director

Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

5

Indications for Use

510(k) Number (if known): K122821

Device Name: CELLTRACKS® AUTOPREP® System

Indications for Use:

The CELLTRACKS® AUTOPREP® System is a laboratory instrument used with immunomagnetic reagents that capture and enrich target cells, and labeling reagents that differentiate cells in whole blood. The CELLTRACKS ANALYZER II® may be used for cell identification and enumeration. The system is for in vitro diagnostic use.

Over-The-Counter Use Prescription Use X AND/OR (21 CFR 801 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

mier lamp

Division Sign-Off

Office of In Vitro Diagnostic
Device Evaluation and Safety

510K K122